India, July 27 -- image credit- shutterstock

Piramal Alternatives has announced the successful conclusion of the investment made by its fund, Piramal Structured Credit Opportunities Fund, in Biodeal Pharmaceuticals, achieving an internal rate of return (IRR) of over 20% following the full redemption of its Rs 110 crore investment.

The successful exit marks the culmination of a value-creating partnership during which Biodeal delivered significant operational and financial progress, strengthening its manufacturing capabilities, governance framework, operational discipline, and laying a strong foundation for its next phase of growth.

The Fund had invested Rs 110 crore in Biodeal in 2024 as part of its strategy of backing high-growth healt...